Longboard Pharmaceuticals to Present at Guggenheim’s Healthcare Talks 4th Annual Immunology and Neurology Day
November 08 2022 - 8:30AM
Business Wire
Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage
biopharmaceutical company focused on developing novel,
transformative medicines for neurological diseases, today announced
that members of its senior leadership team will present in a
fireside chat format at the Guggenheim Healthcare Talks 4th Annual
Immunology and Neurology Day, which is taking place November 14-15,
2022, in New York City.
Presentation Details: Title: Guggenheim Healthcare
Talks 4th Annual Immunology and Neurology Day (In-person)
Details: Participating in a fireside chat on Tuesday,
November 15, 2022 at 2:45pm ET Location: Track 1 - Louis XVI
A
To access a webcast of the presentation, please visit the
“Events & Presentations” page within the Investors Relations
section of Longboard’s website at https://www.longboardpharma.com/.
The fireside chat will be webcast live and archived on the website
for at least 30 days following the event.
About Longboard Pharmaceuticals Longboard
Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company
focused on developing novel, transformative medicines for
neurological diseases. Longboard is working to advance a portfolio
of centrally acting product candidates designed to be highly
selective for specific G protein-coupled receptors (GPCRs).
Longboard’s small molecule product candidates are based on more
than 20 years of GPCR research. Longboard is evaluating LP352, an
oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor
superagonist, with negligible observed impact on 5-HT2B and 5-HT2A
receptor subtypes, in development for the potential treatment of
seizures associated with a broad range of developmental and
epileptic encephalopathies. Longboard is also evaluating LP659, a
centrally acting, sphingosine-1-phosphate (S1P) receptor subtypes 1
and 5 modulator, in development for the potential treatment of
multiple neurological diseases, and LP143, a centrally acting, full
cannabinoid type 2 receptor (CB2) agonist, in development for the
potential treatment of central nervous system (CNS) diseases and
disorders.
Forward-Looking Statements Certain statements in this
press release are forward-looking statements that involve a number
of risks and uncertainties. Such forward-looking statements include
statements about Longboard’s participation in the upcoming
conferences, Longboard’s clinical and preclinical programs, ability
to develop and deliver medicines, and focus. For such statements,
Longboard claims the protection of the Private Securities
Litigation Reform Act of 1995. Actual events or results may differ
materially from Longboard’s expectations. Factors that could cause
actual results to differ materially from those stated or implied by
Longboard’s forward-looking statements are disclosed in Longboard’s
filings with the Securities and Exchange Commission (SEC). These
forward-looking statements represent Longboard’s judgment as of the
time of this release. Longboard disclaims any intent or obligation
to update these forward-looking statements, other than as may be
required under applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221108005363/en/
Corporate Contact: Megan E. Knight Head of Investor
Relations IR@longboardpharma.com 619.592.9775
Longboard Pharmaceuticals (NASDAQ:LBPH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Longboard Pharmaceuticals (NASDAQ:LBPH)
Historical Stock Chart
From Jul 2023 to Jul 2024